Probabilistic economic results generated using a 5-year time horizon
| MM | TAVI | Incremental values | Probability that TAVI is cost-effective at £20 000/QALY threshold (%) | |||||
|---|---|---|---|---|---|---|---|---|
| Parameter | Costs | Benefits | Costs | Benefits | Costs | Benefits | ICER* | |
| Previously published model† | £5000 | 0.80 | £30 200 | 2.36 | £25 200 | 1.56 | £16 200 | 100 |
| ADVANCE high risk vs all PARTNER-B | £13 120 (£11 216, £15 339) | 0.78 (0.73, 0.82) | £35 129 (£30 790, £39 969) | 2.02 (1.87, 2.17) | £22 009 | 1.24 | £17 718 | 83.4 |
| All ADVANCE vs all PARTNER-B | £13 154 (£11 205, £15 055) | 0.78 (0.74, 0.82) | £34 192 (£30 233, £39 369) | 2.29 (2.20, 2.36) | £21 038 | 1.51 | £13 943 | 99.7 |
*All values to be interpreted as £ per QALY gained.
†Watt et al9 2011, 10-year time horizon, base case probabilistic results rounded to nearest £100.
ICER, incremental cost-effectiveness ratio; MM, medical management; QALY, quality-adjusted life-years; TAVI, transcatheter aortic valve implantation.